Abstract
Presentation Description :
Over the last few years, patients with end-stage vision loss (ultra-low vision; ULV: VA ≥ 1.9 logMAR) have increasingly become involved in clinical trials for vision restoration, but there has been a lack of appropriate outcome measures to quantify functional visual ability at baseline and during follow-up. Many of these trials involve small patient numbers at multiple, sometimes international, centers, prompting a need for these measures to be uniform and easily reproducible. A patient-reported outcomes (PRO) for this patient group has been available since 2017 (ULV-VFQ; TVST), but PROs alone are not considered suitable as primary outcome measures by regulatory bodies. For these reasons, over the last 6 years, our lab has developed Wilmer VR, a suite of performance measures based on the items of the ULV-VFQ and covering three visual domains: visual information gathering (Wilmer VRI), visually guided object handling (Wilmer VRH), and visually guided wayfinding (Wilmer VRH). Each module spans a wide difficulty range and has been psychometrically calibrated. The ULV-VFQ and Wilmer VR suite are available for licensing, at no cost to academic institutions, and for a fee to commercial users.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.